Literature DB >> 16360388

Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis.

Mark S Cohen1, William G Dilley, Samuel A Wells, Jeffrey F Moley, Gerard M Doherty, Gregorio A Sicard, Michael A Skinner, Jeffrey A Norton, Mary K DeBenedetti, Terry C Lairmore.   

Abstract

BACKGROUND: The functional results of cryopreserved heterotopic parathyroid autotransplantation (CHPA) are not well defined. The authors evaluated the outcomes of delayed CHPA for the treatment of surgically induced hypoparathyroidism.
METHODS: Since November 1991, 448 parathyroid samples from 436 patients were cryopreserved at our institution. Of these, 29 patients underwent 34 CHPA procedures, with placement of 20 to 25 pieces of parathyroid tissue (approximately 50 to 75 mg) into the forearm. Outcomes were determined based on peripheral parathyroid hormone (PTH) levels and, where available, PTH gradients between grafted and nongrafted arms. Graft function results were defined as completely functional (patients with normal PTH and calcium levels off all calcium/vitamin D supplementation), partially functional (normal PTH levels and mild hypocalcemia on calcium supplementation), or nonfunctional (low PTH levels and dependent on calcium/vitamin D supplementation).
RESULTS: Of the 29 patients with CHPA, prospective data were available for 26 patients undergoing 30 CHPA procedures (9 patients with MEN 1, 4 with MEN 2A, 1 with MEN 2B, and 12 with sporadic hyperparathyroidism). The mean follow-up interval was 2 years. Twelve of 26 patients (46%) had completely functional grafts, 6 patients (23%) had partially functional grafts, and the remaining 8 patients (31%) had nonfunctional grafts. No patient with CHPA had graft-dependent recurrent hyperparathyroidism. Of the 14 patients (15 autografts) with MEN, 7 patients (50%) had fully functional grafts, and 2 patients (14%) had partially functional grafts. The mean cryopreservation period was 7.9 months (range, 1 week to 22 months) for functional autografts and 15.3 months (range, 2 weeks to 106 months) for nonfunctional autografts (P < .01).
CONCLUSIONS: Based on these data and those in previous studies, approximately 60% of delayed, cryopreserved parathyroid autografts are functional. In this study 40% autografts (46% of patients) achieved full competency off supplements. Some patients have evidence of graft function with normal PTH levels but are not normocalcemic. Results were similar for patients with MEN and nonhereditary hyperparathyroidism. The duration of cryopreservation was a significant indicator of graft failure, and no functional autograft was observed beyond 22 months of preservation. CHPA is a useful treatment modality for patients with postoperative hypocalcemia after thyroid or parathyroid surgery, who do not respond to immediate parathyroid autotransplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360388     DOI: 10.1016/j.surg.2005.09.029

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Viability of cryopreserved parathyroid tissue: when is continued storage versus disposal indicated?

Authors:  Marlon A Guerrero; Douglas B Evans; Jeffrey E Lee; Ruijun Bao; Abby Bereket; Swaroop Gantela; Gary D Griffin; Nancy D Perrier
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

2.  Replantation with cryopreserved parathyroid for permanent hypoparathyroidism: a case report and review of literatures.

Authors:  Hai-Guang Liu; Zai-Chong Chen; Xiao-Hua Zhang; Kai Yang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Parathyroid Autotransplantation During Thyroid Surgery: A Novel Technique Using a Cell Culture Nutrient Solution.

Authors:  Fausto Famà; Marco Cicciù; Francesca Polito; Antonio Cascio; Maria Gioffré-Florio; Arnaud Piquard; Olivier Saint-Marc; Alessandro Sindoni
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

Review 4.  Parathyroid transplantation in thyroid surgery.

Authors:  Marcin Barczyński; Filip Gołkowski; Ireneusz Nawrot
Journal:  Gland Surg       Date:  2017-10

Review 5.  Short and long-term impact of parathyroid autotransplantation on parathyroid function after total thyroidectomy.

Authors:  Gabrielle Hicks; Robert George; Mark Sywak
Journal:  Gland Surg       Date:  2017-12

Review 6.  Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.

Authors:  Kerstin Lorenz; Detlef K Bartsch; Juan J Sancho; Sebastien Guigard; Frederic Triponez
Journal:  Langenbecks Arch Surg       Date:  2015-10-02       Impact factor: 3.445

7.  Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Authors:  T Weber; C Dotzenrath; H Dralle; B Niederle; P Riss; K Holzer; J Kußmann; A Trupka; T Negele; R Kaderli; E Karakas; F Weber; N Rayes; A Zielke; M Hermann; C Wicke; R Ladurner; C Vorländer; J Waldmann; O Heizmann; S Wächter; S Schopf; W Timmermann; D K Bartsch; R Schmidmaier; M Luster; K W Schmid; M Ketteler; C Dierks; P Schabram; T Steinmüller; K Lorenz
Journal:  Langenbecks Arch Surg       Date:  2021-04-21       Impact factor: 3.445

Review 8.  Secondary and tertiary hyperparathyroidism, state of the art surgical management.

Authors:  Susan C Pitt; Rebecca S Sippel; Herbert Chen
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

9.  Parathyroid cryopreservation after parathyroidectomy: a worthwhile practice?

Authors:  Kevin Shepet; Amal Alhefdhi; Reid Usedom; Rebecca Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2013-03-16       Impact factor: 5.344

10.  Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.

Authors:  Jeffrey A Norton; David J Venzon; Marc J Berna; H R Alexander; Douglas L Fraker; Stephen K Libutti; Stephen J Marx; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.